Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database
NCT05426239 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1008
Last updated 2022-06-21
Summary
This study is a non-interventional retrospective observational study performed on secondary data from a German multi-site cohort registry, the German national registry of skin cancer (ADOReg).
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-09
- Primary Completion
- 2020-09-07
- Completion
- 2020-09-07
Countries
- Germany
Study Locations
More Related Trials
-
The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany
NCT03205722 ·Status: WITHDRAWN
-
A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy
NCT05432622 ·Status: COMPLETED
-
A Study of Adjuvant Melanoma Stakeholder Treatment Preferences
NCT05115006 ·Status: COMPLETED
-
Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice
NCT05402059 ·Status: UNKNOWN
-
Impact of Obstructive SAS on Metastatic Potential of Cutaneous Melanoma
NCT02699918 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Biomarker-driven Therapy for Melanoma
NCT05063058 ·Status: COMPLETED ·Phase: NA
-
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients
NCT06369428 ·Status: COMPLETED
-
Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma
NCT00849407 ·Status: UNKNOWN
-
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
NCT01709162 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma
NCT01614301 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor.
NCT04625491 ·Status: UNKNOWN
-
Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma
NCT02410863 ·Status: TERMINATED ·Phase: PHASE2
-
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
NCT01253096 ·Status: COMPLETED ·Phase: PHASE2
-
The Impact of Melanoma and Drug Treatment in the Real World
NCT03379454 ·Status: COMPLETED
-
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma
NCT06251934 ·Status: COMPLETED
-
Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC
NCT05741073 ·Status: RECRUITING
-
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom
NCT03448497 ·Status: COMPLETED
-
Gene Expression Profiles and ctDNA for Risk Stratification in Patients With Melanoma
NCT06566404 ·Status: NOT_YET_RECRUITING
-
Investigating Participation Patterns Among Stage IV Melanoma Patients
NCT06093594 ·Status: NOT_YET_RECRUITING
-
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
NCT02297529 ·Status: NO_LONGER_AVAILABLE
-
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
NCT00942162 ·Status: COMPLETED ·Phase: PHASE2
-
Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma
NCT01482260 ·Status: COMPLETED
-
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
NCT01245062 ·Status: COMPLETED ·Phase: PHASE3
-
Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis
NCT07256184 ·Status: COMPLETED
-
Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults
NCT06680323 ·Status: RECRUITING